^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + epacadostat (INCB024360) (IDO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Excerpt:
Patients received escalating doses of oral epacadostat (25, 50, 100, or 300 mg) twice per day plus intravenous pembrolizumab 2 mg/kg or 200 mg every 3 weeks....Among the 12 responders with melanoma, eight had stage M1c disease at baseline, three were BRAF mutation positive, six were PD-L1 positive (melanoma score ≥ 1%), one was PD-L1 negative, four were IDO1 positive, and one was IDO1 negative. Responses were ongoing in 10 of 12 patients.
DOI:
10.1200/JCO.2018.78.9602
Trial ID:
